AAM
AMLX icon

Advisors Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Advisors Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,573
Closed -$9.11K – 1473
2025
Q1 		$9.11K Sell
2,573
-1,329
-34% -$4.73K ﹤0.01% 1412
2024
Q4 		$14.8K Sell
3,902
-3,751
-49% -$17.7K ﹤0.01% 1392
2024
Q3 		$24.8K Sell
7,653
-686
-8% -$1.54K ﹤0.01% 1368
2024
Q2 		$15.8K Sell
8,339
-11
-0.1% -$21 ﹤0.01% 1389
2024
Q1 		$23.7K Sell
8,350
-273
-3% -$3.57K ﹤0.01% 1355
2023
Q4 		$127K Sell
8,623
-20
-0.2% -$307 ﹤0.01% 1172
2023
Q3 		$158K Buy
8,643
+2,780
+47% +$58.8K ﹤0.01% 1141
2023
Q2 		$126K Buy
5,863
+1,218
+26% +$32.9K ﹤0.01% 1181
2023
Q1 		$136K Buy
4,645
+740
+19% +$25.7K ﹤0.01% 1181
2022
Q4 		$144K Buy
+3,905
New +$139K ﹤0.01% 1177

Other funds holding AMLX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Advisors Asset Management's AMLX Position: Q2 2025 in Review

Advisors Asset Management sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2025, closing a stake of 2,573 shares — an estimated $9.11K sold.

Advisors Asset Management first reported a position in AMLX in Q4 2022 and held it in 10 quarters. The position peaked at $158K in Q3 2023. 131 funds tracked by Wall St. Rank hold AMLX as of Q2 2025.

  • Advisors Asset Management reported no remaining Amylyx Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Advisors Asset Management sold 2,573 Amylyx Pharmaceuticals shares in Q2 2025, an estimated $9.11K.
  • Advisors Asset Management first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 10 quarters.
  • Advisors Asset Management's Amylyx Pharmaceuticals position peaked at $158K in Q3 2023.
  • 131 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2025.

Based on Advisors Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.